INTRODUCTION
============

Asthma accounts for more than 1.5 million Emergency Department (ED) visits, one-third of whom are admitted, and more than 5,500 (0.4%) deaths per year.[@b1-0080073] In the setting of acute asthma exacerbation in the ED, inhaled β2-adrenergic agonists, such as albuterol, are the mainstay of treatment. Unfortunately, wide variation exists in how individual patients respond to therapy, a phenomenon well known to emergency physicians. The finding that there are common functional genetic variants of the β2- adrenoreceptor (β2AR) has led to the suggestion that response to therapy may vary from individual to individual depending upon their genotypic makeup.[@b2-0080073],[@b3-0080073],[@b4-0080073],[@b5-0080073],[@b6-0080073]

Single nucleotide polymorphisms (SNPs) are common, single-base pair variations in the DNA. There are some 1.4 million SNPs in the human genome, 60,000 of which are in coding regions. The β2AR gene is located on the long arm of chromosome 5, and thirteen SNPs have been identified in the gene. Two closely linked coding polymorphisms at amino acid positions 16 (A46G) and 27 (C79G) are common in the general population and in controlled outpatient trials have demonstrated to modify the phenotypic response to β2- agonists (46G and 79C being associated with decreased response to inhaled therapy).[@b2-0080073]

In this feasibility study, we examined these two SNPs in an asthmatic population presenting for acute care in the ED. Our goal was to determine whether different genotypes at these two genetic loci affected response to β2-agonists as measured by forced expiratory volume at one second (FEV1).

METHODS
=======

This was an IRB-approved feasibility study of a convenience sample of patients seen in the ED for acute exacerbation of previously diagnosed asthma. Patients for this study were recruited in the ED of a large urban facility serving a local population of some 1.5 million individuals. Patients meeting inclusion criteria were consented and baseline data were obtained, including, age, ethnicity, height (cms) and weight (kg), BMI (kg/m2), smoking history (current, past, never), medication used prior to arrival, and past medical history. An initial set of vital signs including blood pressure (mmHg), respiratory rate and pulse rate as well as pulse oximetry (%) was collected. Prior to the initiation of therapy we also measured FEV1 using incentive spirometery (MicroSpirometer) with the best of three consecutive measurements.

Patients then received standardized care with albuterol-inhaled therapy, receiving 5.0 mg via a hand-held nebulizer every 20 minutes for a total of four treatments. Patients also received 60 mg of prednisone P.O. after the first inhaled treatment. Patients were not administered any other inhaled medications until after completion of the study protocol. Immediately after each inhaled treatment, the patient was reexamined and FEV1 measurements were obtained.

Study patients also underwent phlebotomy to obtain one 10ml green top tube (heparinized vacutainer) for genotype testing. For processing, we utilized an automated specimen component dispensing machine (the Cryo-Bio System). DNA extraction was accomplished on an ongoing basis using the Qiagen 96 DNA Blood Biorobotic Kit.

Genotyping assays were performed using the Taqman assay. Allele-specific probes for use in the TaqMan assay were designed for each of the polymorphic sites within the genes of interest. The oligonucleotide primers for amplification of the polymorphic region are: 5′: CCCAGCCAGTGCGCTTACCT and 3′: CCGTCTGCAGACGCTCGAAC (18). β2AR A(46)G probes used to detect each of the alleles are: GCACCCAATGGAAGCCATG and GCACCCAATACAAGCCATG (21). β2AR C(79)G probes used to detect each of the alleles are: GTCACGCAGCAAAGGGACG and GTCACGCAGGAAAGGGACTG (21).

Statistical Analysis
--------------------

Outcome variables included five separate measurements (one measurement prior to treatment and four measurements after treatment 20 minutes apart) of FEV1. Data analysis related the degree of improvement in FEV1 to the polymorphisms seen in the β2-adrenoreceptor at the two loci in question---A46G (AA homozygyotes, AG heterozygotes, and GG homozygotes) and C79G (CC, CG, and GG). Demographic variables including, age, gender, ethnicity, smoking history, height, weight, body mass index, and medication profile were also considered in our analysis.

Our analyses consider the absolute difference between baseline FEV1 (immediately ***before*** the first inhaled treatment) and that measured at time \#1 (immediately ***after*** the first inhaled treatment) as the primary outcome measure of interest since it was noted in exploratory analyses that subsequent FEV1s (at post-treatments \#2 -- 4) were highly correlated with the first post-treatment measurement, FEV1 \#1 (p-value for all \<0.0001 with Pearson correlation coefficients ranging from 0.92 -- 0.96).

We used analysis of variance to test for differences in the mean FEV1 change among the genotypes at each locus. To adjust for potentially confounding covariates, we also performed multivariable linear regression analyses, with the FEV1 change (first post-treatment minus baseline) as the dependent variable. The independent variables included the two genetic loci as well as the covariates listed above. In the regression model, the genotypes were modeled as the number of 'G' alleles present (0,1,2).

RESULTS
=======

Fifty-three patients were enrolled over a three-month period ([Table 1](#t1-0080073){ref-type="table"}). Twenty-one of these were male and the mean age was 39.7 years (range 19--57 years). Mean baseline FEV1 was 1.17 L/min (range 0.33 to 2.59 L/min) and improved to a mean of 1.42 L/min (range 0.29 -- 3.15) after the first inhaled treatment. Our preliminary analyses revealed that particular polymorphisms were highly correlated such that the presence of a given allele at one locus could predict the allele at the other locus (i.e., the two were in linkage disequilibrium). Specifically, individuals homozygous for the 'A' allele at locus 46 were in all instances homozygous for the 'G' allele at locus 79.

Those individuals who were 79GG homozygotes had a 0.284 L/min improvement in FEV1 (31%) after their initial albuterol treatment compared to 0.123 L/min (12%) in those who were CC homozygotes. This represents a 2.5 times relative difference and a 19% actual difference ([Figure 1](#f1-0080073){ref-type="fig"}). When modeled as an ordinal covariate representing the number of 'G' alleles present, there was a significant positive trend for FEV1 change with increasing numbers of 'G' alleles at the C79G locus (p=0.035). Genotypes at the A46G locus were not associated with FEV1 change in either regression model.

DISCUSSION
==========

β-agonists are the most commonly prescribed asthma medications and the mainstay of therapy in the treatment of acute exacerbation in the ED.[@b8-0080073] The candidate gene approach, which has proved so challenging for complex disease processes such as hypertension, diabetes and cancer, has been fairly successful in identifying variation involved in the treatment of asthma. SNPs have been identified that have pharmacologic implications with regards to response to β~2~ agonists, muscarinic antagonists, 5-LOX inhibitors, CysLT1 antagonists, glucocortocoids, and theophylline.[@b6-0080073] Two of the multiple β~2~-agonists SNP's (A46G and C79G) described in the literature are more common than the others and thus, we believe, more clinically relevant.[@b2-0080073],[@b6-0080073],[@b7-0080073]

The first polymorphism, A46G, has been linked to higher levels of receptor down regulation after exposure to long-term β~2~-agonist therapy.[@b3-0080073],[@b4-0080073] Studies have shown that patients with a 'G' allele have increased nocturnal asthma symptoms, higher airway reactivity, and decreased response to β~2~-agonist therapy.[@b5-0080073] In the setting of an acute asthma exacerbation, these patients may need to resort to alternative forms of management such as corticosteroids or anticholinergics. It has also been suggested that individuals who die due to their asthma represent a group of 46G homozygotes, brittle asthmatics with desensitization of their β~2~ receptor.[@b9-0080073]

The second polymorphism, C79G, appears to serve in protection against desensitization and/or down regulation of the receptor.[@b3-0080073],[@b4-0080073] Patients with the 79G polymorphism exhibit decreased bronchial hyperactivity. Of note, when both the 46G and 79G polymorphisms were present, 46G activity was dominant over 79G in down regulating β~2~-adrenoreceptors and more prevalent in moderate vs. mild asthmatics.[@b10-0080073]

In our study, as patients increased the number of copies of 79C in their β~2~AR gene, their response to inhaled therapy of β~2~-agonists decreased by almost 20%. Interestingly, we were not able to demonstrate an effect of the A46G locus on patients' response to albuterol therapy as measured by FEV1. One explanation for this may be tachyphylaxis in these acutely stressed asthmatics. Given that the β~2~AR in these patients is most likely "pre-desensitized" by endogenous epinephrine and norepinephrine, the lack of a measurable difference is not unexpected.

LIMITATIONS
===========

The primary limitation of this pilot study is the small number of individuals who were 79C homozygotes. In addition the results may have been influenced by the large percentage of patients who received medications prior to contact with EMS or the ED. Their response to therapy may have been attenuated by these prior medications.

CONCLUSION
==========

In this study of acute asthmatics we found a significantly higher rate of improvement for those patients who were 79GG homozygotes in the β~2~AR gene when compared to 79CC homozygotes. While the need to have information about a patient's genotype in an acute care setting such as the ED may not be self-evident, it is the promise of effective patient-specific therapies and the hope of obtaining prognostic information from a patient's genotype that appeals most to the physicians involved in the acute care of patients. Such information may allow a goal-directed approach for individual patients and will allow the practitioner to predict the clinical course over the initial two- to four-hour time period of emergency care. In the setting of asthma, the long term potential of such information may be measured by fewer intubations, fewer hospitalizations and fewer deaths.[@b1-0080073]
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###### 

Characteristics of the individuals included in FEV analyses (n=54)

  Category Predictor                                         Number [\*](#tfn3-0080073){ref-type="table-fn"} (\#) or Mean   Percent (%) or Std. Dev.   Range
  ---------------------------------------------------------- -------------------------------------------------------------- -------------------------- --------------
  **DEMOGRAPHICS**                                                                                                                                     
  **Ethnicity**                                                                                                                                        
  African-American                                           11                                                             20.4%                      
  Caucasian                                                  6                                                              11.1%                      
  Latino/Latina                                              36                                                             66.7%                      
  **Age**                                                    39.9                                                           10.8                       19--57
  **Gender**                                                                                                                                           
  Male                                                       21                                                             38.9%                      
  Female                                                     32                                                             59.3%                      
  **GENOTYPE**                                                                                                                                         
  **A46G Genotype**[1](#tfn1-0080073){ref-type="table-fn"}                                                                                             
  AA                                                         13                                                             24.1%                      
  AG                                                         29                                                             59.3%                      
  GG                                                         11                                                             20.4%                      
  **C79G Genotype**[2](#tfn2-0080073){ref-type="table-fn"}                                                                                             
  CC                                                         4                                                              7.4%                       
  CG                                                         12                                                             22.2%                      
  GG                                                         38                                                             70.4%                      
  **COVARIATES**                                                                                                                                       
  **Smoking**                                                                                                                                          
  Current                                                    17                                                             31.5%                      
  Past                                                       16                                                             29.6%                      
  Never                                                      20                                                             37.0%                      
  **Body Mass Index**                                                                                                                                  
  Height (cm)                                                167.8                                                          31.5                       142.2--193.0
  Weight (kg)                                                89.0                                                           25.6                       52--163.6
  BMI (kg/m^2^)                                              31.6                                                           8.3                        18.5--56.6
  **Inhaled Asthma Medications Prior to Arrival**                                                                                                      
  None                                                       18                                                             33.3%                      
  Yes                                                        35                                                             66.6%                      
  **OUTCOME**                                                                                                                                          
  **Forced Expiratory Volume**                                                                                                                         
  Baseline FEV (n=50)                                        1.16                                                           0.63                       0.33--2.59
  FEV, time \#1 (n=52)                                       1.41                                                           0.68                       0.29--3.15
  FEV, time \#2 (n=52)                                       1.54                                                           0.67                       0.27--2.95
  FEV, time \#3 (n=48)                                       1.53                                                           0.67                       0.25--3.17
  FEV, time \#4 (n=38)                                       1.62                                                           0.76                       0.25--3.17
  **Disposition**                                                                                                                                      
  Home                                                                                                                      53                         100%

[@b1-0080073]A46G Genotype Frequency A: 0.52, G: 0.48

[@b2-0080073]C79G Genotype Frequency C: 0.19, G: 0.81

Numbers may not add to total sample size due to missing genotype data.
